An alternative formulation called pentadecapeptide arginate exists specifically to navigate around this constraint
This could include: Heart rate assessment at 4-8 weeks after initiation or dose escalation Periodic electrocardiography if arrhythmias are suspected Patient self-monitoring of pulse if symptomatic palpitations occur Evaluation of heart rate control in patients with atrial fibrillation When evaluating tachycardia in patients on GLP-1 therapy, clinicians should assess for other potential causes, including dehydration (especially from GI side effects), anemia, hyperthyroidism, stimulant use, infection, or other medications
Not all do, so ask upfront
Children, lactating or pregnant women, and individuals who are sensitive to caffeine are advised against consuming this drink
Dispose of the Medication Safely Do not throw the vial in the regular trash or flush it down the toilet